DSciLab
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DSciLab - overview
Established
2022
Location
Shanghai, Shanghai, China
Primary Industry
Biotechnology
About
Founded in 2022 and based in Suzhou, China, DSciLab is a biotech company that focuses on the development of mRNA drugs. Changyou Zhan, the company's CSO and founder, is also a distinguished professor of Fudan University and the head of the key innovation team of Shanghai "Gao Jian". In February 2023, the company completed the Shanghai R&D Lab. In October 2025, DSciLab raised a series A funding from new investor JenKem Technology Co.
, Ltd. and returning investor Fosun Health Capital. DSciLab developed Intelligent Screening Platform for Delivery Systems to launch main products, library of lipid nano-delivery systems and liver-targeted delivery systems. The liver-targeted delivery system completes animal experimental verification and IIT clinical verification services for the development of mRNA drugs for rare liver diseases.
DSciLab generates revenue by providing construction of mRNA drug lipid nanodelivery system libraries and mRNA drug development services. The company will focus on its clinical demand-driven drug development process.
Current Investors
Fosun Health Capital, Shanghai Creation Investment, JenKem Technology Co., Ltd.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Pharmaceutical Research & Development
Website
ww.dscilaboratory.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.